Virtmed gains $43 million in second round of fundingVirtmed has secured more than $43 million from investors in its second round of funding. Among the investors are eHealth Technology Fund, New Enterprise Associates, Frazier & Co., and the
Virtmed has secured more than $43 million from investors in its second round of funding. Among the investors are eHealth Technology Fund, New Enterprise Associates, Frazier & Co., and the venture arm of 3Com. Virtmed is a three-year-old Cambridge, MA, firm that is banking on the integration of wireless devices, Internet technologies, and existing healthcare information systems to give doctors and nurses access to patient and other data at the point of care.
Virtmeds primary product is a thin-client server designed to sit on-site and direct data between existing databases and handheld devices. The firm has also developed online reporting functions to allow users to update patient charts remotely.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.